ArticleBMC infectious diseases2025
Genetic polymorphism of Plasmodium falciparum using merozoite surface proteins 1 and 2 (msp-1 and msp-2) genes in Oveng and Mintom, South region of Cameroon.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Genetic diversity of the IC/3D7 allelic family of the merozoite surface protein 2 (MSP2) of Plasmodium falciparum and multiplicity of infection in four health facilities in the Mbouda Health District, Cameroon.Scientific reports · 2026Article
- Genetic Diversity and Allelic Distribution ofJournal of parasitology research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMalaria remains a critical public health issue in Cameroon, where Plasmodium falciparum is the predominant species responsible for severe clinical cases. Investigating the genetic diversity and multiplicity of infection (MOI) of P. falciparum is essential for understanding transmission dynamics, immune evasion, and the effectiveness of control strategies. This study aimed to characterize the allelic polymorphism and MOI of P. falciparum isolates collected in Oveng and Mintom, two selected health areas within the Dja et Lobo Division, a malaria-endemic area in southern Cameroon.
methodsGenomic DNA was extracted from dried blood spots collected from infected individuals. P. falciparum detection and species confirmation were performed using a multiplex polymerase chain reaction (PCR). Genotyping of msp1 allelic families (KI, MAD20, and RO33) and msp2 allelic families (FC27, 3D7) was conducted via nested PCR. Fragment analysis was used to determine allelic variants and estimate MOI.
resultsA total of 315 P. falciparum isolates were successfully amplified and genotyped. For msp1, 12 distinct alleles were identified (3 for KI, 7 for MAD20, and 2 for RO33), with fragment sizes ranging from 172 to 300 bp. For msp2, 28 alleles were detected (14 for each FC27 and 3D7allelic families), with fragment sizes ranging from 200 to 800 bp. For msp2, the FC27 allelic family was the most prevalent (100%), followed by 3D7 (98.4%). For msp1, K1 was detected in 87.8% of samples, while MAD20 and RO33 were present in 75.2% and 74.9% of isolates, respectively. The number of clones per infection ranged from 1 to 7, with 99% of samples exhibiting polyclonal infections. The mean MOI was significantly higher for msp2 compared to msp1 (4.85 vs. 2.40; p < 0.05). Expected heterozygosity was 0.83 for msp1 and 0.98 for msp2, indicating high genetic diversity.
conclusionThe observed high allelic diversity and elevated MOI among P. falciparum isolates suggest intense malaria transmission in the study areas. These findings underscore the need to strengthen local malaria control interventions and provide valuable baseline data for future surveillance and vaccine development efforts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.